Our Research

Our Research Pipeline

Microbial Biotherapeutics

For the treatment of a variety of inflammatory conditions and bacterial infections

Autoimmune conditions

Rheumatoid Arthritis

Inflammatory Bowel Disease

Psoriasis

Conditions

Arthritis

Atopic Dermatitis

Gastrointestinal Infections

(Clostridium difficile, Helicobacter pylori)

Engineered Protein

For the treatment of autoimmune diseases

Product/Compound Indication Status
R&D Early Stage Late Stage IND/HREC Phase 1 Phase 2 Phase 3
Live Microbial Biotherapeutics (LMB) - Clinical Candidates
SVT-1C469 H. Pylori Infection
SVT-1A710 IBD-UC
SVT-1B149 Chronic Idiopathic Constipation (CIC) / IBS-C
LMB Development Projects
SVT-1A167 IBD-Crohns
SVT-3A4610 / SVT-3A4710 Atopic Dermatitis, Dermatological Conditions
SVT-1E167 / SVT-3A4710 ICB associated Colitis
LMB Combination/Adjunct Therapeutics Development Projects
SVT-1A4710 / SVT-1D167 + immunosuppressants RA/IBD/Psoriasis
Engineered Protein
SVT-MCHo (1-10) / SVT-Bax (1-10) RA, Psoriasis

Microbial Biotherapeutics

Microbial Biotherapeutics

A primary research focus for Servatus is the development of microbial biotherapeutics (live micro-organisms) which can be used to prevent or treat disease.

Historically, the application of selected bacterial strains has been devoted to the modulation and repair of the gut microbiome. However, Servatus’ research concentrates on developing microbial biotherapeutics that are applicable to the prevention, treatment or cure of specific diseases or conditions in humans.

Servatus targets autoimmune and inflammatory conditions associated with dysbiosis and immune dysregulation, including ulcerative colitis, arthritis, atopic dermatitis, and gastrointestinal and urogenital tract infections.

Servatus utilises bacterial strains that have not been widely employed previously. They have demonstrated bioactive properties that inhibit pathogenic bacterial growth and infection, modulate immune responses and regulate inflammatory signals.

The efficacy of the bacterial strains is due to structures on their cell surface and, importantly, the biological effector molecules they secrete, which interact and communicate with the body’s own cells.

The bacterial candidates are developed to act directly at specific sites within the gastrointestinal tract and at targeted organ sites that are influenced by microbial interactions.

Engineered Protein

Engineered Protein

Servatus’ research is directed at selectively improving specific characteristics of existing therapeutic proteins.

Servatus has designed and produced modified derivatives with better solubility and half-life characteristics to cater to the growing market for therapeutic proteins with new modes of action.

Servatus focuses on proteins that have demonstrated clear clinical utility and data in human disease. Through rational redesign of key features, Servatus improves the protein’s bioavailability, half-life or biological potency.

Servatus applies state-of-the-art computation to design protein variants in silico to engineer improved characteristics with direct application to their clinical performance.

These protein variants are then rapidly cloned and expressed in amounts suitable for physico-chemical and pre-clinical assays. The assays screen for the most suitable protein variants to be tested in animal disease models prior to clinical testing to confirm their improved clinical utility.

Research Platforms and IP

Research Platforms and IP

Servatus has two platforms: Engineered Protein for the treatment of autoimmune diseases, and Microbial Biotherapeutics for the treatment of inflammatory conditions and bacterial infections.

The treatment of autoimmune diseases, such as rheumatoid arthritis and psoriasis, remains a major medical challenge, with current medicines unable to satisfactorily treat a large number of autoimmune diseases and often generating unpleasant side effects.

Servatus is engineering recombinant proteins to improve their clinical utility and boost their potential to provide more-effective treatment of autoimmune diseases, with minimal side effects.

In parallel, in one of the most exciting areas of global drug development, Servatus is developing live biotherapeutics for the treatment of microbiome-associated conditions, such as Inflammatory Bowel Disease (ulcerative colitis) and gastrointestinal conditions (C.diff infection and H.pylori infection).

Servatus has completed preliminary research work on both the Engineered Protein and Microbial Biotherapeutics and is proceeding with advanced pre-clinical work ahead of anticipated clinical trials.

Servatus’ core intellectual property and patents include a patent on “the directed alteration for improving clinical performance of selected protein drugs”. The company holds other patents for various microbial biotherapeutics, including for the treatment of wound infections, respiratory infections, inflammatory conditions, and conditions of the gastrointestinal tract.

Servatus’ goal is to commercialise its proprietary technology and engage with one or more corporate partners in the biopharmaceutical industry.